RWC-340B Issues Press Statement Regarding PrEP Bill
Click below to see RWC-340B’s Press Statement PrEP BIll Press Statement RWC-340B
RWC-340B Decries Gilead Policies, Seeks Immediate Relief
RWC-340B President, Shannon Stephenson, received a response to the May 4th follow-up and original letters sent to Gilead. Click Here to see Gilead’s response, and Click Here to read Shannon’s…
RWC-340B Submits Comments to Federal Trade Commission
As you may know, the Federal Trade Commission recently requested public comments on the impacts of Pharmacy Benefit Managers’ practices, affecting drug affordability and access. Today, RWC-340B submitted detailed…
RWC-340B Sends Letters to Gilead, HHS Secretary, and OPA Director.
A growing number of pharmaceutical manufacturers have recently posed restrictions affecting Ryan White Clinics and other Safety Net Providers. RWC-340B has taken action to address these challenges head-on. On…
Johnson & Johnson is the 16th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies
By letter dated March 21, 2021, Johnson & Johnson (J&J) announced that, effective May 2, 2022, it will no longer honor bill-to/ship-to orders for contract pharmacy arrangements with hospitals unless…
Trent Smith hired as RWC-340B Managing Director
Trent Smith is the Managing Director for RWC-340B under UPHS and brings experience from both the nonprofit and for-profit sectors, having worked within the Southern Scholarship Foundation Community and then…
RWC-340B Responds to Gilead’s Conditions on 340B Contract Pharmacy
As reported today in the 340B Report, Health Care Provider Groups Slam Gilead’s Conditions on 340B Contract Pharmacy (for subscribers only), and RWC-340B President Shannon Stephenson is quoted throughout (excerpt below). Ryan White…
Gilead to Restrict Access to 340B Prices at Contract Pharmacies for Branded Hep-C Drugs; AbbVie Adds Imbruvica to Restrictive Contract Pharmacy Policy
By letter dated March 15, 2022, Gilead announced that, effective May 2, 2022, it will implement a new “Contract Pharmacy Integrity Initiative” under which it will no longer honor contract…
RWC-340B Sends Gilead Letter Requesting Exceptions for MAP/PAP Policies
Please see the attached letter to Mr. Charles Clapton, VP of Federal Governmental Affairs with Gilead from RWC-340B President, Shannon Stephenson on behalf of RWC-340B requesting exceptions to MAP/PAP Policies. Should you…
Pfizer and GSK Announce Policies to Restrict Access to 340B Drugs at Contract Pharmacies; Novo Nordisk Modifies Its Policy
Pfizer and GlaxoSmithKline (“GSK”) are the 13th and 14th manufacturers, respectively, to restrict 340B pricing on drugs shipped to contract pharmacies. Novo Nordisk, which previously restricted access to 340B pricing to one…